Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
B 6.03 0.00% 0.00
OMER closed unchanged on Wednesday, November 20, 2024, on 63 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Volume Surge Other 1.86%
Upper Bollinger Band Walk Strength 1.86%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 17 hours ago
Up 2% about 17 hours ago
Bullish 180 Entry about 20 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 20 hours ago
1,2,3, Pullback Entry about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Omeros Corporation Description

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Surgery Inflammation Disorders Clinical Research Ophthalmology Clinical Trial Urology Schizophrenia Macular Degeneration Cataracts Perfusion Wet Age Related Macular Degeneration Hemoglobin Surgical Specialties Movement Disorders Cognitive Disorders Ischemia Addiction Intraocular Lens Arthroscopy Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.51
52 Week Low 1.8166
Average Volume 589,451
200-Day Moving Average 4.04
50-Day Moving Average 4.29
20-Day Moving Average 4.79
10-Day Moving Average 5.33
Average True Range 0.46
RSI (14) 66.33
ADX 39.52
+DI 43.17
-DI 17.35
Chandelier Exit (Long, 3 ATRs) 6.12
Chandelier Exit (Short, 3 ATRs) 5.40
Upper Bollinger Bands 6.64
Lower Bollinger Band 2.95
Percent B (%b) 0.83
BandWidth 77.10
MACD Line 0.53
MACD Signal Line 0.34
MACD Histogram 0.185
Fundamentals Value
Market Cap 379.08 Million
Num Shares 62.9 Million
EPS -2.89
Price-to-Earnings (P/E) Ratio -2.09
Price-to-Sales 4.93
Price-to-Book 8.44
PEG Ratio -0.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.50
Resistance 3 (R3) 6.51 6.35 6.42
Resistance 2 (R2) 6.35 6.23 6.35 6.40
Resistance 1 (R1) 6.19 6.16 6.27 6.19 6.37
Pivot Point 6.04 6.04 6.08 6.04 6.04
Support 1 (S1) 5.88 5.92 5.96 5.87 5.69
Support 2 (S2) 5.72 5.84 5.72 5.66
Support 3 (S3) 5.56 5.72 5.64
Support 4 (S4) 5.56